Want to see LGND full AI Analyst Report?
LGND Stock Chart & Stats
$231.82
-$2.36(-2.14%)
At close: 4:00 PM EST
$231.82
-$2.36(-2.14%)
Day’s Range― - ―
52-Week Range$111.72 - $320.99
Previous CloseN/A
Volume21.09K
Average Volume (3M)233.52K
Market Cap
$6.33B
Enterprise Value$5.61B
Total Cash (Recent Filing)$779.40M
Total Debt (Recent Filing)$451.98M
Price to Earnings (P/E)40.5
Beta0.89
Next Earnings
Aug 11, 2026EPS Estimate
1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.84
Shares Outstanding20,041,061
10 Day Avg. Volume267,372
30 Day Avg. Volume233,523
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue20.44
Enterprise Value/Gross Profit20.73
Enterprise Value/Ebitda25.25
Forecast
1Y Price Target
$280.67Price Target Upside21.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)9.06
Revenue Forecast (FY)$286.95M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent, high trailing‑twelve‑month operating and free cash flow that nearly matches net income indicates durable cash conversion and high earnings quality. This provides recurring internal funding for royalty purchases, milestone support, and buybacks, reducing reliance on dilutive financing over the medium term.
Scalable Royalty Aggregation ModelThe shift to a partnership/royalty aggregation model with a lean operating base and an 18‑deal track record shows a repeatable, asset‑light strategy. Lower fixed costs and a dedicated deal team enable scalable growth, margin preservation, and faster accretion as new royalties ramp, strengthening long‑term profitability.
Strong Liquidity To Fund GrowthNearly $1 billion of available capital and stated intent to deploy $150–$250M annually into new royalties gives Ligand capacity to pursue accretive deals and realize scale benefits. This liquidity underpins strategic optionality, supports integration of XOMA assets, and mitigates short‑term funding risk for multi‑year growth.
Bears Say
Partner Execution DependenceRevenue and cashflow are structurally tied to third‑party development, regulatory and commercial timing. Successful royalties require partner execution, approvals and reimbursement — factors outside Ligand’s control — producing persistent timing risk and lumpy recognition that can materially swing results across quarters and years.
GAAP Earnings Volatility From Fair‑value MarksSignificant mark‑to‑market swings from equity holdings create recurring GAAP volatility and occasional reported losses despite strong underlying operations. This reduces transparency of core royalties, complicates forecasting and could affect lender covenants, investor confidence, and tax/timing outcomes over multiple reporting periods.
Convertible Financing Adds Dilution/overhangLarge zero‑coupon convertible issuance materially increases liquidity but creates potential long‑term equity overhang via conversion features, hedges and warrants. That contingent dilution can pressure per‑share metrics if converts or warrants are exercised, and the step‑up in leverage reduces balance sheet flexibility in downside scenarios.
Ligand Pharma News
LGND FAQ
What was Ligand Pharmaceuticals Inc’s price range in the past 12 months?
Ligand Pharmaceuticals Inc lowest stock price was $111.72 and its highest was $320.99 in the past 12 months.
What is Ligand Pharmaceuticals Inc’s market cap?
Ligand Pharmaceuticals Inc’s market cap is $6.33B.
When is Ligand Pharmaceuticals Inc’s upcoming earnings report date?
Ligand Pharmaceuticals Inc’s upcoming earnings report date is Aug 11, 2026 which is in 41 days.
How were Ligand Pharmaceuticals Inc’s earnings last quarter?
Ligand Pharmaceuticals Inc released its earnings results on May 07, 2026. The company reported $1.63 earnings per share for the quarter, missing the consensus estimate of $1.816 by -$0.186.
Is Ligand Pharmaceuticals Inc overvalued?
According to Wall Street analysts Ligand Pharmaceuticals Inc’s price is currently Undervalued.
Does Ligand Pharmaceuticals Inc pay dividends?
Ligand Pharmaceuticals Inc pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharmaceuticals Inc dividends here
What is Ligand Pharmaceuticals Inc’s EPS estimate?
Ligand Pharmaceuticals Inc’s EPS estimate is 1.99.
How many shares outstanding does Ligand Pharmaceuticals Inc have?
Ligand Pharmaceuticals Inc has 20,041,061 shares outstanding.
What happened to Ligand Pharmaceuticals Inc’s price movement after its last earnings report?
Ligand Pharmaceuticals Inc reported an EPS of $1.63 in its last earnings report, missing expectations of $1.816. Following the earnings report the stock price went down -9.555%.
Which hedge fund is a major shareholder of Ligand Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$280.67 (21.07% Upside)
$280.67 (21.07% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
175.11%
12-Months-Change
Fundamentals
Return on Equity
16.19%
Trailing 12-Months
Asset Growth
69.21%
Trailing 12-Months
Company Description
Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was broadly positive: the company reported strong underlying operating momentum (royalty revenue +56% YoY, total revenue +14% YoY, adjusted EPS +23% YoY), meaningful near-term and long-term growth catalysts (Filspari approval and Palvella Phase III success), a transformative announced acquisition (XOMA) expected to be immediately accretive and to materially scale the portfolio, and a strong liquidity position. Key risks discussed include GAAP volatility from equity fair-value movements, lumpy Captisol/contract revenue and timing dependence on partner execution, and remaining uncertainty until the XOMA transaction closes and its tax attributes are fully quantified. Overall, the positives — including multiple high-value clinical and commercial catalysts and a materially enlarged, diversified portfolio — outweigh the highlighted near-term financial and timing uncertainties.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$280.67
▲(21.07% Upside)
Technical Analysis
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
2.65% Insiders
45.39% Mutual Funds
18.35% Other Institutional Investors
7.17% Public Companies and
Individual Investors